Imaizumi Satoshi

イマイズミサトシ | Imaizumi Satoshi

Affiliation and department：

Research field (1)： Internal medicine - General

Research theme for competitive and other funds (6)：

2022 - 2025 Dietary pattern and HDL function
2018 - 2023 ナノバブル化アポA-I模倣ペプチドと超音波による新規動脈硬化治療法の開発
2017 - 2020 Novel biomarker for atherosclerosis: clinical significance of isoprostanes analyzed by LC-MS/MS
2014 - 2017 Development of new treatment strategy in peripheral artery disease using apoA-I mimetic peptide
2014 - 2017 Exploration of HDL functional measurement as a novel biomarker for atherosclerosis

Show all

Papers (112)：

Kohei Takata, Satoshi Imaizumi, Atsushi Iwata, Bo Zhang, Emi Kawachi, Shin-Ichiro Miura, Masahiro Ogawa. Associations of High-Density Lipoprotein Functionality with Coronary Plaque Characteristics in Diabetic Patients with Coronary Artery Disease: Integrated Backscatter Intravascular Ultrasound Analysis. Biomolecules. 2023. 13. 9
Hang Zhang, Tomohiro Komatsu, Shihoko Nakashima, Satomi Abe, Emi Kawachi, Satoshi Imaizumi, Keijiro Saku, Yoshinari Uehara. HDL Mimetics Enhances Mitochondrial Function via Stimulation of PGC1-α. European Cardiology Review. 2023. 18
Satoshi Imaizumi, Yuhei Shiga, Masahiro Ogawa, Hideto Sako, Yoshihisa Nagata, Akira Matsunaga, Tetsuro Shirotani, Fumihiro Hoshino, Eiji Yahiro, Yuko Uehara, et al. Correction to: Randomized trial of an increased dose of calcium channel blocker or angiotensin II type 1 receptor blocker as an add-on intensive depressor therapy in type 2 diabetes mellitus patients with uncontrolled essential hypertension: the ACADEMIE Study. Heart and vessels. 2020. 35. 4. 603-604
今泉聡, 池周而. ApoA-I模倣ペプチドFAMPと超音波/マイクロバブルを併用した新規動脈硬化治療. 福岡大学研究部論集. 2019
Satoshi Imaizumi, Yuhei Shiga, Masahiro Ogawa, Hideto Sako, Yoshihisa Nagata, Akira Matsunaga, Tetsuro Shirotani, Fumihiro Hoshino, Eiji Yahiro, Yuko Uehara, et al. Randomized trial of an increased dose of calcium channel blocker or angiotensin II type 1 receptor blocker as an add-on intensive depressor therapy in type 2 diabetes mellitus patients with uncontrolled essential hypertension: the ACADEMIE Study. Heart and vessels. 2019. 34. 4. 698-710

ｍore...

MISC (21)：

S. Imaizumi, K. Takata, E. Yahiro, E. Kawachi, A. Iwata, Y. Uehara, B. Zhang, S. Miura, K. Saku. Inhibition of lipopolysaccharide induced gene expression by HDL from healthy subjects and patients with acute myocardial infarction. EUROPEAN HEART JOURNAL. 2016. 37. 217-218
Y. Hitaka, M. Ogawa, S. Goto, Y. Nagata, J. Morii, S. Imaizumi, T. Yasuda, N. Matsumoto, A. Matsunaga, K. Saku. Comparison of circadian laboratory measurements of coagulation assays between administrations of rivaroxaban and warfarin in patients with non-valvular atrial fibrillation. EUROPEAN HEART JOURNAL. 2015. 36. 225-225
K. Takata, A. Iwata, S. Imaizumi, B. Zhang, S. Miura, K. Saku. Impact of anti-oxidative capacity of high-density lipoprotein on vulnerability of coronary plaques in patients with type 2 diabetes mellitus. EUROPEAN HEART JOURNAL. 2015. 36. 346-346
S. Imaizumi, A. Iwata, K. Takata, B. Zhang, S. Miura, K. Saku. Relation between high-density lipoprotein efflux capacity and coronary plaque progression in type 2 diabetes patients with intensive lipid-lowering therapy. EUROPEAN HEART JOURNAL. 2015. 36. 812-812
E. Kawachi, S. Imaizumi, K. Takata, S. Abe, Y. Matsuo, E. Yahiro, Y. Uehara, B. Zhang, S. Miura, K. Saku. Effect of smoking cessation on HDL function. EUROPEAN HEART JOURNAL. 2014. 35. 902-902

ｍore...

Books (9)：

10. 日本医師会生涯教育シリーズ97 動脈硬化診療のすべて IV. 動脈硬化研究のトピックス A. 基礎研究 3. カナキヌマブ
日本医師会 2019
循環器疾患最新の治療2018-2019 XVI 3.脂質異常症(高脂血症)
2018
最新冠動脈疾患学(下)-冠動脈疾患の最新治療戦略- 4. 慢性心筋梗塞 (2)慢性心筋梗塞の治療 1)薬物療法 2二次予防薬
2016
そうだったんだ!脂質異常症 I. One Point Advice. 高HDL血症は高リスク?
2016
そうだったんだ!脂質異常症 I. Controversy. 飲酒でHDLが増加する?
2016

ｍore...

Professional career (2)：

博士(医学)
学士(医学)

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page